Reply To: Avacta

#4489
Nick Hargrave
Keymaster

https://www.londonstockexchange.com/news-article/AVCT/first-patient-dosed-in-fifth-cohort-of-ava6000/15905590

First C5 patient dosed having had the trial change approved in order to increase the dosing levels given safety profile to date